UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

 

FORM 8-K

 

CURRENT REPORT

Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934

 

Date of Report (Date of Earliest Event Reported): September 13, 2018

 

PLx Pharma Inc.
(Exact name of registrant as specified in its charter)
     
Delaware 001-36351 46-4995704
(State or Other Jurisdiction
of Incorporation)
(Commission
File Number)
(IRS Employer
Identification No.)
     
8285 El Rio Street, Ste. 130, Houston, Texas 77054
(Address of Principal Executive Offices) (Zip Code)

 

Registrant’s Telephone Number, Including Area Code: (713) 842-1249

 

 
(Former Name or Former Address, If Changed Since Last Report)

 

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions ( see General Instruction A.2. below):

 

☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

 

☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

 

☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

 

☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

 

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company ☒

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐ 

 

 

 

Item 5.07 Submission of Matters to a Vote of Security Holders.

 

On September 13, 2018, PLx Pharma Inc. (the “Company”) held its 2018 annual meeting of stockholders (the “Annual Meeting”). At the Annual Meeting, the Company’s stockholders were asked to vote upon the following:

1. The election of each of Gary Balkema, Kirk Calhoun, Robert Casale, John Hadden II, Michael Valentino and Natasha Giordano to serve as directors until the Company’s 2019 annual meeting of stockholder and until their successors are duly elected and qualify;
2. The ratification of the appointment of Marcum LLP as the Company’s independent registered public accounting firm for the fiscal year ending December 31, 2018; and
3. The approval of the Company’s 2018 Incentive Plan.

The results of the matters voted on at the Annual Meeting, based on the presence in person or by proxy of holders of record of 7,068,052 of the 8,735,862 shares of the Company’s common stock entitled to vote, were as follows:

1. The election of each of Gary Balkema, Kirk Calhoun, Robert Casale, John Hadden II, Michael Valentino and Natasha Giordano to serve as directors until the Company’s 2019 annual meeting of stockholder and until their successors are duly elected and qualify was approved as follows:
  For Withheld Broker Non-Votes
Gary Balkema 3,262,791 138,417 3,666,844
Kirk Calhoun 3,276,482 124,726 3,666,844
Robert Casale 3,276,582 124,726 3,666,844
John Hadden II 3,276,482 124,726 3,666,844
Michael Valentino 3,357,752 43,456 3,666,844
Natasha Giordano 3,357,752 43,456 3,666,844

 

2. The stockholders ratified the appointment of Marcum LLP as the Company’s independent registered public accounting firm for the fiscal year ending December 31, 2018. The voting results were as follows:
For Against Abstain Broker Non-Votes
6,912,569 3,665 151,818 --

 

3. The stockholders adopted and approved the Company’s 2018 Incentive Plan. The voting results were as follows:
For Against Abstain Broker Non-Votes
3,171,192 30,295 199,721 3,666,844

 

 

 

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

 

 

  PLX PHARMA INC.
   
   
Dated: September 19, 2018 By:

/s/ Natasha Giordano

    Name: Natasha Giordano
    Title: President and Chief Executive Officer

 

PLx Pharma (NASDAQ:PLXP)
Historical Stock Chart
From Feb 2024 to Mar 2024 Click Here for more PLx Pharma Charts.
PLx Pharma (NASDAQ:PLXP)
Historical Stock Chart
From Mar 2023 to Mar 2024 Click Here for more PLx Pharma Charts.